- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03751293
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
May 13, 2019 updated by: Hebei Yanda Ludaopei Hospital
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peihua Lu, PhD&MD
- Phone Number: +86-0316-3306393
- Email: Peihua_lu@126.com
Study Locations
-
-
Hebei
-
Sanhe, Hebei, China, 065200
- Recruiting
- Hebei yanda Ludaopei Hospital
-
Contact:
- Peihua Lu, PhD&MD
- Phone Number: +86-0316-3306393
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Volunteered to participate in this study and signed informed consent.
- Age 18-70 years old, male or female.
- Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014).
Patients with relapsed or refractory multiple myeloma who meet at least one of the following conditions:
- Subjects must have received at least two therapy regimens (including proteasome inhibitor or immune-modulator therapy, disease progress or relapse after the last therapy).
- Subjects have received only one therapy regimen, but the investigators judge that patients have unmet treatment needs or can't get benefit from current treatment options.
Subjects have one or more measurable multiple myeloma lesion, must include one of the following conditions:
- Serum M protein≥1 g/dl(10g/L)
- Urine M protein≥200 mg/24h
- Serum free light chain(sFLC): κ/λ ratio abnormal and ≥10 mg/dl
- Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
- At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy.
- ECOG scores 0 - 1.
- Normal cardiac diastolic function, left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography), no serious arrhythmia.
- No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
- No contraindications of leukapheresis.
- Expected survival > 12 weeks.
- Female subjects in childbearing age, their serum or urine pregnancy test must be negative,until 7 days before cell therapy and all subjects must agree to take effective contraceptive measures during the trial.
Exclusion Criteria:
- Have a history of allergy to cellular products.
- Any kind of these laboratory testing: including but not limited to,serum total bilirubin≧1.5mg/dl, serum ALT, AST≧2.5×ULN, serum creatinine≧2.0mg/dl, Hb (hemoglobin)<80g/L, neutrophils<1000/mm^3, platelets≦50000/mm^3 or platelet count maintained by transfusion.
- Subjects with the following clinically significant cardiovascular diseases.
- A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease.
- Use any anticoagulant (except aspirin).
- Patients requiring urgent treatment due to tumor progression or spinal cord compression.
- Patients with CNS metastasis or symptoms of CNS involvement.
- The investigators judge that any increase in the risk of the subject or interference with the results of the trial.
- After allogeneic hematopoietic stem cell transplantation.
- Plasma cell leukemia.
- One week before leukapheresis and one week before CART cell infusion, treated with more than 5mg/d prednisone (or equal amount of other corticosteroids).
- Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy.
- Uncontrolled active infection.
- Prior treatment with CAR T therapy or any other genetically modified T cell therapy.
- Live vaccine inoculation within four weeks before enrollment.
- Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons.
- Have a history of alcoholism, drug addiction and mental illness.
- Participated in any other clinical trial within three months.
- The investigators believe that there are other circumstances that are not suitable for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: C-CAR088
Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
|
Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0
x 10^6 anti-BCMA CAR+ T cells/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: The incidence of treatment-emergent adverse events (TEAEs)
Time Frame: 30 days
|
The incidence of treatment-emergent adverse events (TEAEs)
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: 12 months
|
12 months
|
|
Progression free survival (PFS)
Time Frame: 6 months, 12 months
|
6 months, 12 months
|
|
The CART cell duration in vivo
Time Frame: 12 months
|
The copys of BCMA-CART DNA in peripheral blood with qPCR method
|
12 months
|
The soluble BCMA changes in peripheral blood
Time Frame: 12 months
|
The amount of soluble BCMA in peripheral blood with ELISA method
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2019
Primary Completion (Anticipated)
October 30, 2019
Study Completion (Anticipated)
October 30, 2020
Study Registration Dates
First Submitted
November 15, 2018
First Submitted That Met QC Criteria
November 20, 2018
First Posted (Actual)
November 23, 2018
Study Record Updates
Last Update Posted (Actual)
May 15, 2019
Last Update Submitted That Met QC Criteria
May 13, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- 0203-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Multiple Myeloma
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Clinical Trials on C-CAR088
-
Institute of Hematology & Blood Diseases HospitalUnknownMultiple MyelomaChina
-
Peking Union Medical College HospitalCellular Biomedicine Group Ltd.UnknownMultiple MyelomaChina
-
Institute of Hematology & Blood Diseases HospitalCellular Biomedicine Group Ltd.Recruiting
-
The First Affiliated Hospital with Nanjing Medical...UnknownRelapsed or Refractory Multiple MyelomaChina
-
IlDong Pharmaceutical Co LtdCompleted
-
International Centre for Diarrhoeal Disease Research...University of California, DavisCompletedMalnourished Children
-
University of MiamiRecruitingHypoplastic Left Heart SyndromeUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedAdvanced CancerUnited Kingdom
-
Direction Centrale du Service de Santé des ArméesRecruitingEating Habit | Cold Exposure | HeatFrance